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An influenza pandemic poses a serious threat to humans and animals. Conventional treatments against
influenza include two classes of pathogen-targeting antivirals: M2 ion channel blockers (such as aman-
tadine) and neuraminidase inhibitors (such as oseltamivir). Examination of the mechanism of influenza
viral infection has shown that endosomal acidification plays a major role in facilitating the fusion
between viral and endosomal membranes. This pathway has led to investigations on vacuolar ATPase
(v-ATPase) activity, whose role as a regulating factor on influenza virus replication has been verified in
extensive genome-wide screenings. Blocking v-ATPase activity thus presents the opportunity to interfere
with influenza viral infection by preventing the pH-dependent membrane fusion between endosomes
and virions. This study aims to apply diphyllin, a natural compound shown to be as a novel v-ATPase
inhibitor, as a potential antiviral for various influenza virus strains using cell-based assays. The results
show that diphyllin alters cellular susceptibility to influenza viruses through the inhibition of endosomal
acidification, thus interfering with downstream virus replication, including that of known drug-resistant
strains. In addition, combinatorial treatment of the host-targeting diphyllin with pathogen-targeting
therapeutics (oseltamivir and amantadine) demonstrates enhanced antiviral effects and cell protection
in vitro.
 2013 Elsevier B.V. All rights reserved.1. Introduction
An influenza pandemic poses a serious threat to humans and
animals, and it has incurred great financial and societal cost for
decades. The most common pathogens causing influenza in hu-
mans are type A influenza viruses (seasonal H1N1, pandemic
H1N1 and H3N2) and type B influenza viruses. Conventional treat-
ments against the disease include two classes of antivirals: M2 ion
channel blockers adamantanes (amantadine and rimantadine) and
neuraminidase (NA) inhibitors (oseltamivir, peramivir, zanamivir
and laninamivir) (Ison, 2011; Lee and Yen, 2012). These two cate-
gories are designed to target viral proteins, thereby interfering
with the virus’ infection mechanisms. However, the emergence of
new influenza viral strains carrying drug resistant mutations that
can outpace the development of pathogen-targeting antivirals pre-sents a major clinical challenge. Most circulating influenza A
viruses show resistance to adamantanes (Ison, 2011; Jackson
et al., 2011; Lee and Yen, 2012; Moscona, 2009), and intrinsic resis-
tance to the compound has also been observed in Influenza B (Ison,
2011). In addition, beginning with the 2007–2008 influenza sea-
son, circulating seasonal H1N1 viruses possessing the oseltamivir
resistance mutation (His275Tyr) have been observed (Lackenby
et al., 2008). Since the first reported case of pandemic H1N1 in
2009, oseltamivir-resistant variant strains have also been identi-
fied (Baz et al., 2009; Leung et al., 2009; Speers et al., 2010; Storms
et al., 2012). The rapid development of antiviral resistance high-
lights the need for alternative therapeutic strategies.
Influenza virus is an RNA virus that undergoes rapid mutations
under the selective pressure of drug use. Pathogen-targeting anti-
viral drugs that interact with specific viral enzymes can therefore
be rendered ineffective against a mutant population. In contrast,
host-targeting therapeutics intervening with infection pathways
offers the sustained therapeutic potential regardless of viral
mutation.
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facilitated by a low endosomal pH (Stertz and Shaw, 2011), is a ma-
jor event of the influenza infection cascade. Vacuolar ATPase (v-
ATPase) activity, which is responsible for pumping protons into
endosomal compartments, has been identified as a requirement
for influenza virus replication in previous studies (Guinea and
Carrasco, 1995; Muller et al., 2011; Perez and Carrasco, 1994). V-
ATPase-encoding genes have also been identified in several gen-
ome-wide screens for host factors regulating influenza virus repli-
cation, and the knockdown of v-ATPase subunits has been shown
to result in significant inhibition of influenza virus replications
(Chin and Brass, 2012; Hao et al., 2008; Karlas et al., 2010; Konig
et al., 2010; Mehle and Doudna, 2010). Blocking v-ATPase activity,
therefore, presents an opportunity to impede influenza infection
by preventing the low pH-dependent membrane fusion between
endosomes and virions. In addition to influenza viruses, flavivi-
ruses (Pierson and Diamond, 2012), vaccinia viruses (Townsley
et al., 2006), rhabdoviruses (Albertini et al., 2012), and coronavi-
ruses (Belouzard et al., 2012) also enter target cells in a pH-depen-
dent fashion.
Diphyllin, a natural compound isolated from Cleistanthus colli-
nus, has recently been identified as a novel v-ATPase inhibitor that
can inhibit lysosomal acidification in human osteoclasts (Sorensen
et al., 2007) and reduce v-ATPase expression in gastric adenocarci-
noma cells (Shen et al., 2011). This study aims to characterize the
application of diphyllin as an antiviral for various influenza virus
strains in two types of cell lines. Bafilomycin A1, a macrolide anti-
biotic and a specific inhibitor of vacuolar ATPase which inhibits
growth of type A and type B human influenza viruses in MDCK cells
(Ochiai et al., 1995) was included in key functional assays as a con-
trol. In addition, combinatorial effects between the diphyllin and
pathogen-targeting therapeutics, including oseltamivir and aman-
tadine, were assessed to evaluate diphyllin’s potential in enhancing
existing influenza therapies.2. Materials and methods
2.1. Compounds
Diphyllin (ChemBridge, San Diego, CA) (Charlton et al., 1996;
Fukamiya and Lee, 1986) was dissolved in dimethyl sulfoxide
(DMSO, Fisher Scientific), and oseltamivir carboxylate and amanta-
dine hydrochloride (Sigma) were dissolved in sterile water. For all
three compounds, 10 mM primary stocks and 100 lM working
stocks were made in respective solvents and stored at 20 C.
Bafilomycin A1 (Sigma) was dissolved in DMSO to make a 10 lM
working stock. Right before each experiment, compounds were
freshly diluted in culture media to achieve desired concentrations.2.2. Cells and viruses
Mardin-Darby canine kidney (MDCK) cells and A549 cells (both
from ATCC) were maintained in DMEM supplemented with 10% fe-
tal bovine serum, 100 units/ml penicillin, and 100 lg/ml strepto-
mycin. For the influenza virus infection experiments in MDCK
cells, cells were overlaid with DMEM supplemented with 0.2%
BSA, 25 mM HEPES buffer, and 2 lg/ml TPCK-treated trypsin. Re-
agents for cell culture were purchased from Invitrogen. All incuba-
tion and infection steps were carried out at 37 C and with 5% CO2
unless otherwise specified.
NS1-GFP virus, with a background of A/PuertoRico/8/34(H1N1)
(Manicassamy et al., 2010) was kindly provided by Dr. Aldolfo Gar-
cia-Sastre at Mount Sinai School of Medicine, New York. Two refer-
ence influenza virus strains A/Aichi/2/68(H3N2) (VR-547) and B/
Taiwan/2/62 (VR-1735) were purchased from ATCC. In addition,three human influenza virus isolates, A/San Diego/21/
2008(H1N1), A/San Diego/61/2008(H1N1), and A/San Diego/1/
2009(H1N1 pdm09) were used in this study. Avian influenza virus
A/Duck/Yilan/2904/99(H6N1) was isolated from duck in Yilan, Tai-
wan. All types of influenza viruses were propagated in MDCK cells
and titrated with plaque assays as previously described (Szretter
et al., 2006). The dengue virus serotype 2 (DENV2) strain S221, a
triple-plaque-purified clone from a clinical isolate, was cultured
and titrated with plaque assays as previously described (Yauch
et al., 2009).
2.3. In vitro cytotoxicity assay of diphyllin
MDCK cells and A549 cells were grown in a 96-well clear poly-
styrene microplate (Corning) at a density of 10,000 cells per well
1 day prior to experiment. Diphyllin was twofold serially diluted
in cell media and added to the cell monolayer in four replicates.
The final DMSO concentration was no more than 0.5% in all wells.
After 3 days, the culture supernatant was removed and 100 ll of
MTT reagent (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazoli-
um bromide, 1 mg/ml in PBS) was added to each well and incu-
bated at 37 C for 3 h. Next, MTT was removed and 100 ll of
DMSO was added to each well to solubilize the purple formazan
crystals. Absorbance values were measured at 570 nmwith a refer-
ence wavelength of 650 nm on a Tecan Infinite M200 reader (Tecan
Group, Männedorf, Switzerland). Control cell wells (without
diphyllin treatment) were assumed to represent 100% cell viability.
Normalized cell viability data were plotted against diphyllin con-
centrations and fitted to a non-linear regression curve using
Graphpad Prism (GraphPad Software, San Diego, CA). The 50% cyto-
toxicity concentration (CC50, the concentration of diphyllin at
which cellular viability was reduced to 50%) was obtained
accordingly.
2.4. Acridine orange labeling
Confluent cultures of MDCK cells or A549 cells in 96-well black
polystyrene clear bottom microplates (Corning) were incubated
with bafilomycin A1 or various concentrations of diphyllin in four
replicates at 37 C for 20 min. Acridine orange (1 lg/ml in media)
(Molecular probes) was then distributed to each well and incu-
bated at 37 C for an additional 10 min before wash. Fluorescence
images were obtained and data was quantified on iCys Research
Imaging Cytometer (Compucyte, Westwood, MA) using 488 nm
excitation/532 nm emission filters for green fluorescence and
560 nm excitation/610 nm emission filters for red fluorescence.
2.5. Time-of-addition assay of diphyllin
MDCK cells were seeded in a 12-well plate (200,000 cells/well)
1 day before experiment to obtain cultures with 80% confluency.
Diphyllin (2 lM) was added to the cells at three different time
points relative to virus infection: 1 h prior to infection, same time
as infection, or 1 h after infection. Untreated wells were used as
controls. In this experiment, NS1-GFP virus at a multiplicity of
infection (MOI) of 0.01 was used to infect the cells. After a 1-h per-
iod of infection, all test cells were washed and overlaid with fresh
media containing 2 lM of diphyllin. After 24 h, the cells were
washed and lysed to analyze viral nucleoprotein (NP) expression
using Western blotting (Section 2.11).
2.6. In vitro antiviral activity assay of diphyllin
The following method regarding cellular incubation with
diphyllin and virus infection was used throughout this study to
examine the antiviral effect of diphyllin. Various concentrations
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prior to infection by the human influenza viruses or the DENV2,
both at an MOI of 0.01. For the avian influenza H6N1 virus, an
MOI of 0.1 on MDCK cells was used. After a 1-h period of infection,
cells were washed, overlaid with fresh media containing the same
concentrations of diphyllin as in previous step, and incubated for
another 24 h (40 h for avian influenza H6N1 virus). Infected cells
without diphyllin treatment were used as controls. Next, cells were
either fixed for fluorescence microscopy examination of GFP
expression (Section 2.9), or lysed for real-time quantitative RT-
PCR (Section 2.10) and Western blotting (Section 2.11). In addition,
cell culture supernatant from test wells was harvested to deter-
mine virus titers with a 50% tissue culture infectious dose (TCID50)
assay and hemagglutination (HA) test (for influenza viruses, Sec-
tion 2.12) or with plaque assay (for DENV2, Section 2.12).
2.7. Cell cytopathic effect (CPE) inhibition assay and determination of
IC50 of compounds
The CPE inhibition assay was used to determine the IC50 of com-
pounds (the concentration of compound showed 50% inhibition of
virus-induced CPE) against various influenza virus strains. Briefly,
MDCK cells were seeded in 96-well microplates (20,000 cells/well)
1 day before experiment to obtain 80% confluency. When testing
diphyllin or amantadine, serial dilutions of the compounds were
added to MDCK cells 1 h prior to virus infection at an MOI of
0.01. An MOI of 0.06 was used for strain A/SanDiego/21/
2008(H1N1). After a 1-h period of infection, all test wells were
washed and overlaid with fresh media containing identical com-
pound concentrations as in the previous step. For oseltamivir, in-
stead of pretreatment, the compound was added to cells after the
1-h period of infection. Twenty-four hours later, cellular viability
was examined by an MTT assay, as described in Section 2.3. In-
fected cells without any compound treatment were assumed to
represent 0% cell viability and cells without infection and com-
pound treatment were assumed to represent 100% cell viability.
Normalized cell viability data were plotted against diphyllin con-
centrations and fitted to a nonlinear regression curve in Graphpad
Prism (GraphPad Software) to generate the IC50.
2.8. Compound combinations treatment assay
Antiviral activity from combinations of diphyllin vs. oseltamivir
or diphyllin vs. amantadine was tested using the same treatment
protocol as described in Section 2.7 using virus strains NS1-GFP
and A/Aichi/2/68(H3N2) for infection, respectively. Cells were har-
vested for NP expression analysis using Western blotting (Sec-
tion 2.11), and extracellular virus titers in supernatant were
determined by an HA test (Section 2.12). In addition, the CPE inhi-
bition assay, as described in Section 2.7, was conducted to examine
the cell protection effect.
2.9. Fluorescence microscopy of GFP-expressing influenza virus
Cells grown in 96-well microplates (Corning) were treated with
diphyllin or bafilomycin A1 and infected with NS1-GFP virus as de-
scribed in Section 2.6. Cells were then fixed with 4% paraformalde-
hyde, stained with 40,6-diamidino-2-phenylindole, dihydrochloride
(DAPI, KPL), and imaged using the DeltaVision deconvolution
microscope system (Applied Precision, Issaquah, WA). Digital
images of blue and green fluorescence were acquired using DAPI
and FITC filters, respectively. Images were overlaid and deconvo-
luted using softWoRx software. In the experiments for fluorescence
quantification, cells were grown in 96-well clear bottom black
polystyrene microplates (Corning) and GFP fluorescence intensity
was quantified using an imaging cytometer (iCys), as describedin Section 2.4. Infected cells without any compound treatment
were assumed to represent 0% fluorescence intensity and cells
without infection and compound treatment were assumed to rep-
resent 100% fluorescence intensity. Normalized data were plotted
against diphyllin concentrations.
2.10. Real-time quantitative RT-PCR
Total RNA of MDCK cells and of A549 cells was extracted using
RNeasy Mini Kit (Qiagen) and viral RNA from the cell culture super-
natant was extracted using QIAamp viral RNA Mini kit RNA (Qia-
gen) according to the manufacturer’s manual. For influenza
viruses, real-time quantitative RT-PCR was performed with
qScript™ One-Step SYBR Green qRT-PCR Kit (Quanta BioSciences,
Gaithersburg, MD) using previously published primers that target
the M1 gene of influenza A virus (Ward et al., 2004) and canine
b-actin (Wang et al., 2011). Briefly, the reaction mixture was re-
verse-transcribed at 50 C for 10 min; heated at 95 C for 5 min;
underwent 45 cycles of 95 C for 10 s, 55 C for 20 s, and 72 C
for 30 s; followed by first-derivative melting curve analysis on
ABI 7900HT System (Applied Biosystems). All reactions were set
up in triplicate and the obtained Ct values were normalized to b-
actin. The relative influenza virus M1 gene expression (fold change
of untreated control) was determined by a 2DDCt method (Livak
and Schmittgen, 2001). For the dengue virus, a probe-based quan-
titative RT-PCR was performed and virus titers were determined
based on genome equivalents (GE) as previously described (Yauch
et al., 2009).
2.11. Western blot analysis
MDCK cells or A549 cells were lysed in SDS sample buffer (Invit-
rogen) and disrupted by sonication. Cell lysate proteins were sep-
arated on NuPAGE Bis–Tris 4–12% gel (Invitrogen) following the
manufacturer’s instructions, and transferred onto 0.45 lm pore
sized PVDF membranes (Immobilon, Milipore Corp.). Protein blots
were probed with influenza virus anti-NP antibody (culture super-
natant from ATCC hybridoma clone No. H16-L10-4R5) or anti-
tubulin antibody (#A01410, GenScript) at room temperature for
an hour. To detect the protein signals, the membranes were incu-
bated in sheep anti-mouse IgG HRP conjugate (#NA931, Amer-
sham) at a 1:3,000 dilution for another hour and then developed
using ECL Plus Western blotting detection reagents kit
(Amersham).
2.12. Quantification of viruses with 50% tissue culture infectious dose
assay, hemagglutination test, and plaque assay
Fifty percent tissue culture infectious dose (TCID50) assay and
hemagglutination (HA) test were performed as previously de-
scribed (Szretter et al., 2006) on culture supernatant containing
influenza viruses. Chicken red blood cells (1%) were used in HA
tests of avian influenza virus, and guinea pig red blood cells (1%,
Lonza) were used in those of human influenza virus strains. Plaque
assay on dengue virus was conducted as previously described
(Yauch et al., 2009).
2.13. Statistical analysis
Throughout this study, data were analyzed and plotted using
Graphpad Prism (GraphPad Software). Viral titer and cell viability
were compared by analysis of variance (ANOVA) followed by Dun-
nett’s multiple comparisons test. All error bars represent standard
deviation (SD). Values of p < 0.05 were considered significant.
⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, and ⁄⁄⁄⁄p < 0.0001.
374 H.-W. Chen et al. / Antiviral Research 99 (2013) 371–3823. Results
3.1. Drug cytotoxicity of diphyllin
A standard MTT assay was used to determine the cytotoxicity of
diphyllin on MDCK cells and A549 cells. After 3 days of incubation,
the CC50 of diphyllin were 3.48 ± 0.17 and 24.01 ± 0.45 lM
(mean ± SD) in MDCK cells and in A549 cells, respectively (Fig. 1).3.2. Diphyllin inhibits endosomal acidification in MDCK cells and A549
cells
The weak base, pH-sensitive dye acridine orange was used in
this study to investigate the effect of diphyllin on the acidification
of endosomes in MDCK cells and A549 cells. Once the dye was ta-
ken by live cells, acidic endosomes in cells were stained red by pro-
tonated acridine orange, whereas non-acidic endosomes were
stained green. As seen in Fig. 2A, in comparison to the extensive
red-stained endosomes in untreated cells, the addition of bafilomy-
cin A1 (0.2 lM) or diphyllin (0.078, 0.312, 1.25 lM) showed de-
creased acidic endosomes and increased non-acidic endosomes in
cells. The degree of inhibition in endosomal acidification was
shown to correlate with diphyllin concentration. To quantitatively
analyze the endosomal acidification, green and red fluorescence
data collected from diphyllin-treated wells were compared, and
the green/red fluorescence ratio was evaluated as indicated in
Fig. 2B. Diphyllin treatment resulted in a dose-dependent quench-
ing of red fluorescence in cytoplasmic vesicles. These data suggest
diphyllin inhibits endosomal acidification in MDCK cells and A549
cells.3.3. Pretreatment/treatment with diphyllin alters the cellular
susceptibility to influenza virus
In this study, 2 lM of diphyllin was added to MDCK cells at
three different time points relative to virus infection and was incu-
bated with cells for 24 h after the 1-h infection period. Compared
to the untreated control, diphyllin treatment before, during, and
after infection all resulted in reduced mRNA level of viral matrix
gene and reduced expression of viral NP in cells (Fig. 3A). Further-
more, cellular exposure to diphyllin prior to virus infection re-Fig. 1. Drug cytotoxicity of diphyllin in MDCK cells and A549 cells. Various
concentrations of diphyllin were added to MDCK cells and A549 cells and incubated
for 3 days. An MTT assay was performed and cell viability was normalized to the
value of untreated controls (100%). Data in the plot present the mean ± SD out of
four test replicates. The CC50 of diphyllin were 3.48 ± 0.17 and 24.01 ± 0.45 lM in
MDCK cells and A549 cells, respectively.sulted in the maximal inhibition effect on viral replication based
on Western blotting analysis, indicating that diphyllin treatment
was most effective at altering the cellular susceptibility to virus
infection in a pretreatment setting. Therefore, the pretreatment
method was applied to all the following experiments.
3.4. Diphyllin showed an antiviral activity against the GFP-expressing
influenza virus
The NS1-GFP influenza virus was applied in this study to inves-
tigate the antiviral activity of diphyllin. The intracellular viral
mRNA and protein expression were examined in the absence or
presence of diphyllin pretreatment with MDCK cells and A549
cells. The results showed that the relative level of influenza viral
matrix gene mRNA decreased by 5-fold and 2-fold in the presence
of 2 and 1 lM of diphyllin, respectively, as compared to the un-
treated controls in MDCK cells. As also indicated in Fig. 3B (left pa-
nel), this phenomenon was in agreement with the viral NP
expression profile obtained from Western blot analysis. Similarly,
dose-dependent reduction of viral NP expression with diphyllin
treatment was observed in A549 cells. As low as 0.5 lM of diphyl-
lin pretreatment to cells resulted in a 50% reduction of viral mRNA
transcription as compared to the untreated control (Fig. 3B, right
panel). An HA test was conducted to further examine the released
viral particle from the MDCK cells. The supernatant of the MDCK
cell culture pretreated with 1 or 0.5 lM of diphyllin prior to virus
infection revealed significantly lower HA titer as compared to
those of the untreated control (Fig. 3C). These results demonstrate
that diphyllin has a dose-dependent antiviral effect against NS1-
GFP influenza virus.
The NS1-GFP influenza virus stably expresses GFP after virus
replication; in other words, no GFP is detectable in viruses or cells
unless viral replication occurs. Therefore, imaging and quantifica-
tion of GFP fluorescence based on fluorescence imaging can be
used to evaluate the extent of virus entry and replication. As seen
in Fig. 4A, with the reference of the DAPI-stained nuclei, GFP pro-
duced from virus replication was observed to localize in the cyto-
plasm. GFP fluorescence was reduced with pretreatment of
bafilomycin A1 or increased concentrations of diphyllin in MDCK
cells. Through quantification of GFP fluorescence, the relative
intensity from test wells demonstrated a dose-dependent decrease
in the presence of diphyllin. The dose–response curves of GFP
intensity found in diphyllin-treated MDCK and A549 cells are
shown in Fig. 4B.
3.5. Inhibition of the replication of avian influenza virus and dengue
virus serotype 2
To further validate the viral inhibitory effect of diphyllin, an
H6N1 avian influenza virus duck isolate and a plaque-purified
DENV2 strain were also tested. The results showed that viral titer
of A/Duck/Yilan/2904/99 (H6N1) was dose-dependently reduced
with diphyllin treatment. In particular, incubation with 2 lM of
diphyllin entirely abrogated growth of avian influenza virus in
MDCK cells (Fig. 5A, left). Similar dose-dependent viral HA titers
were also detected (Fig. 5B, right). Furthermore, in the context of
DENV2 infection in A549 cells, dose-dependent reduction of extra-
celluar (Fig. 5B, left) and intracellular (Fig. 5B, right) viral titer were
observed with diphyllin treatment compared to the untreated
controls.
3.6. Diphyllin demonstrated an antiviral effect against various types/
subtypes of human influenza virus strains
In addition to the H1N1-background NS1-GFP virus, avian
influenza A H6N1 virus, and dengue virus serotype 2, major
(A)
(B)
Fig. 2. Dose-dependent inhibition of endosomal acidification caused by diphyllin. MDCK cells and A549 cells were incubated with bafilomycin A1 (0.2 lM) or various
concentrations of diphyllin (0.078, 0.312, 1.25 lM) at 37 C for 20 min. Untreated cells (media only) were used as controls. Acridine orange dye (1 lg/ml) was added to each
well and incubated for 10 min. (A) Acidic endosomes in cells were stained red by acridine orange and non-acidic endosomes were stained green. Fluorescence images were
obtained on iCys Research Imaging Cytometer. Representative images are shown (magnification: 40). (B) Fluorescence data was collected from diphyllin-treated wells and
the green/red fluorescence ratio was presented. Data in the plot present the mean ± SD out of four replicates. (For interpretation of the references to color in this figure legend,
the reader is referred to the web version of this article).
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ployed in this study to test the antiviral effect of diphyllin. These
test strains included clinical isolates of seasonal H1N1, 2009 pan-
demic H1N1, two reference strains of H3N2 and type B influenza
virus, and a plaque-purified DENV2 strain. As indicated in
Fig. 6A–D, diphyllin treatment (0.125–1 lM) resulted in an overall
dose-dependent reduction of viral HA titer against all fourinfluenza virus strains compared to untreated controls. These re-
sults suggest that diphyllin possesses a broad-spectrum antiviral
activity against multiple types/subtypes of influenza viruses.
The IC50 of diphyllin, amantadine or oseltamivir against various
influenza virus strains was determined by the CPE inhibition assay,
and the results were listed in Table 1. Diphyllin exhibited IC50 val-
ues in the nanomolar range against all the tested virus strains.
(A) (C)
(B)
Fig. 3. Pretreatment/treatment with diphyllin alters the cellular susceptibility to influenza virus and showed an antiviral activity against influenza virus. (A) Two lM of
diphyllin was added to MDCK cells at three different time points relative to NS1-GFP virus infection (MOI = 0.01): 1 h prior to infection (1 hpi), same time as infection (0 hpi)
or 1 h after infection (1 hpi). Infected cells without diphyllin treatment were used as controls. After a 1-h infection period, all test cells were washed and incubated with fresh
media containing 2 lM of diphyllin and incubated for 24 h. Cells were then harvested and the expression of viral NP and tubulin was detected by Western blotting. (B)
Various concentrations of diphyllin were added to MDCK cells (left panel) or A549 cells (right panel) 1 h before the NS1-GFP virus infection (MOI = 0.01). Infected cells
without diphyllin treatment were used as controls. After a 1-h period of infection, cells were washed, overlaid with fresh media containing the same concentrations of
diphyllin as in previous step, and incubated for another 24 h. Cells were lysed and the mRNA level of viral matrix gene relative to cellular b-actin was determined by
quantitative RT-PCR. Results were presented as fold change of untreated control (upper panel). Expression of intracellular viral NP and tubulin was detected by Western
blotting (lower panel). (C) Extracellular viral titers in culture supernatant were determined with HA tests. Values are mean ± SD from three replicates. Viral titers between
each treated group and the untreated control group were compared by one-way ANOVA followed by Dunnett’s multiple comparisons test. (ns: non-significant, ⁄p < 0.05,
⁄⁄p < 0.01).
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38.32 ± 0.51 nM (mean ± SD) against the A/Aichi/68(H3N2) strain,
and a relatively higher IC50 was observed against the H1N1
pdm09 strain (IC50 = 632.2 ± 3.67 nM). Furthermore, the clinical
isolate A/San Diego/21/2008(H1N1) that carries a drug-resistant
mutation (H275Y) in the NA gene, as determined by DNA sequenc-
ing (data not shown), was found to be sensitive to the diphyllin
treatment with an IC50 of 372.8 ± 8.17 nM, despite the virus’ strong
resistance to oseltamivir (IC50 > 40,000 nM). Similarly, A/PR/8/34
showed resistance to amantadine (IC50 > 22,000 nM) but was sen-
sitive to diphyllin (IC50 = 489.1 ± 14.32 nM).3.7. Compound combinations of diphyllin and oseltamivir or
amantadine demonstrated an improved antiviral effect and enhanced
cell protection
Antiviral activity and CPE inhibition provided from combinato-
rial treatments were evaluated in this study. As presented in
Fig. 7A, a combination of diphyllin (1000 or 500 nM) and oseltam-
ivir (1000, 500 or 250 nM) resulted in enhanced viral NP reduction,
as compared to the single-drug treatment with each compound.
Lower amounts of extracellular virus from the combination treat-
ment were also confirmed by an HA test. In addition, by combining
(A)
(B)
Fig. 4. Diphyllin inhibited the GFP expression from the NS1-GFP influenza virus. 0.2 lM of bafilomycin A1 or various concentrations of diphyllin (0.078, 0.312, 1.25 lM) were
added to MDCK cells 1 h before NS1-GFP virus infection (MOI = 0.01). Infected cells without diphyllin treatment were used as controls. After a 1-h period of infection, cells
were washed, overlaid with fresh media containing the same concentrations of diphyllin as in previous step, and incubated for another 24 h. (A) Fluorescence images of GFP
(green) and nucleus (DAPI, blue) were acquired using DeltaVision deconvolution microscope system. Representative images are shown (magnification: 200). (B) Green
fluorescence intensity from diphyllin-treated cells was quantitated using an iCys Research Imaging Cytometer. Data was presented by the relative intensity of untreated
controls cells. Values are mean ± SD from four replicates. (For interpretation of the references to color in this figure legend, the reader is referred to the web version of this
article).
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showed enhanced cell protection against the influenza virus
(Fig. 7B). For instance, at the dose of 3.125 nM, oseltamivir alone
resulted in only 5.13% in cell viability, whereas the combinatorial
treatment with 125 nM of diphyllin showed a 3.88-fold increase
in cell viability (19.96%). Increasing the dose of diphyllin from
125 to 250 nM further improved the cell viability by 8-fold to
41.12%, which was superior to that achieved by 25 nM oseltamivir
alone (24.89% in cell viability).
Similar enhancement in antiviral effect and cell protection were
observed across the various doses of diphyllin and amantadine
combinations as indicated in Fig. 8 using the same methodology
to assess the intracellular/extracellular virus production and CPE
inhibition. The combinations of diphyllin (500 or 250 nM) and
amantadine (100, 50 or 25 nM) demonstrated enhanced inhibitionon the viral NP expression and virus particle release as compared
to the individual compound treatment (Fig. 8A). The combinatorial
addition of diphyllin (250 or 125 nM) to amantadine (25, 12.5, 6.25
or 3.125 nM) also increased the cell viability after virus infection at
all indicated doses (Fig. 8B). Taken together, combinatorial treat-
ment with diphyllin and oseltamivir or with diphyllin and amanta-
dine demonstrated enhanced antiviral effect and cell protection.4. Discussion
Diphyllin is one of the newly discovered v-ATPase inhibitors
(Huss and Wieczorek, 2009). By including an old v-ATPase inhibi-
tor, bafilomycin A1, as a control in two key functional assays, a
similar cellular mechanism of action between diphyllin and
(A)
(B)
Fig. 5. Diphyllin inhibited virus replication of H6N1 avian influenza virus and dengue virus serotype 2. (A) MDCK cells were pretreated with diphyllin 1 h prior to strain A/
Duck/Yilan/2904/99(H6N1) infection at an MOI of 0.1. Infected cells without diphyllin treatment were used as controls (black bars). After a 1-h period of infection, cells were
washed, overlaid with fresh media containing the same concentrations of diphyllin as in previous step, and incubated for another 40 h. The cell culture supernatant was
harvested for TCID50 assay (left) and HA test (right), respectively. (B) A549 cells were treated with diphyllin using the same procedures as above, and the DENV2 was
inoculated for infection (MOI = 0.01). Twenty-four hours later, the culture supernatant and cells were harvested to determine the virus titers using plaque assay (left) and
real-time quantitative RT-PCR (right), respectively. Values are mean ± SD from three replicates. Viral titers between each treated group and the untreated control group were
compared by one-way ANOVA followed by Dunnett’s multiple comparisons test. (ns: non-significant, ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, ⁄⁄⁄⁄p < 0.0001).
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itors have been discovered, including benzolactone enamides sali-
cylihalamide, lobatamide A and B, apicularen, indolyls, oximidine,
macrolactone archazolid, lobatamide C, cruentaren, diphyllin and
recently reported synthetic compounds, such as FR202126 and
SB 242784 (Huss and Wieczorek, 2009; Niikura, 2006; Perez-Sa-
yans et al., 2009). Many of these v-ATPase inhibitors have been
previously evaluated for their antiviral activity against influenza
viruses (Guinea and Carrasco, 1995; Muller et al., 2011; Ochiai
et al., 1995), rhinoviruses (Suzuki et al., 2001), and dengue viruses
(Duan et al., 2008). Even though some of the classical v-ATPase
inhibitors exhibited potent inhibitory effect against influenza
viruses, the high toxicity of these compounds made them unsuit-
able for clinical applications (Drose and Altendorf, 1997; Niikura,
2006). In Muller’s study (2011), for instance, bafilomycin A1
showed limited therapeutic efficacy in vivo despite significant viral
inhibition in vitro. Implicated to have an unselective action mech-
anism, bafilomycin A1 exhibited high toxicity and inflicted liver
and spleen damages at a 350 ng/kg. In contrast, a structurally dis-
tinctive saliphenylhalamide, demonstrated effective in vivo antivi-
ral effect in mice and was well tolerated at a dose of 7 mg/kg. The
improved antiviral effect/toxicity profile of saliphenylhalamide
was attributed to a more selective v-ATPase inhibiting mechanism
and highlights a major factor for consideration in therapeutic
applications of v-ATPase inhibitors. Regarding diphyllin in the
present study, compound safety has been demonstrated in aprevious report (Shen et al., 2011), in which daily treatment in
mice at a dose of 20 mg/kg was tolerated for 10 days without sig-
nificant signs of toxicity. Structurally, both saliphenylhalamide and
diphyllin fall into the class of benzolactones. It should be noted,
however, that saliphenylhalamide is a lactone of salicylic acid,
and diphyllin is a lactone of naphthoic acid, and saliphenylhala-
mide contains a macrocyclic N-acyl enamine functional group that
has been shown to be required for potent v-ATPase activity (Lebr-
eton et al., 2008), whereas diphyllin has no such functional group.
Owing to the multiple isoforms of v-ATPase expressed in a tissue-
specific manner (Toei et al., 2010), the therapeutic usefulness of v-
ATPase inhibitors relies on the selectivity in the inhibition (Niikura,
2006). Although the tissue or isoforms specific inhibition of diphyl-
lin has yet been determined, diphyllin in this study demonstrates a
safe therapeutic window in two types of mammalian cell lines with
IC50 values against viruses in the nanomolar range (38–632 nM),
and the cellular cytotoxicity in the micromolar range (3–24 lM),
suggesting a potential role for further in vivo studies. We believe
broad-spectrum antiviral agents of high potency and low toxicity
may be further developed through the existing compounds or
derivatives.
The effect of diphyllin on endosomal acidification was moni-
tored by vital staining with acridine orange using scanning flow
cytometry. In agreement with previous work in human osteoclast
cell cultures (Sorensen et al., 2007), diphyllin dose-dependently
quenched the acidic cytoplasmic vesicles within a short period of
(A) (B)
(D)(C)
Fig. 6. Diphyllin inhibited virus production against major types/subtypes of human influenza virus strains. (A–D) MDCK cells were pretreated with diphyllin 1 h prior to four
different influenza virus strains infection at an MOI of 0.01. Infected cells without diphyllin treatment were used as controls (black bars). After a 1-h period of infection, cells
were washed, overlaid with fresh media containing the same concentrations of diphyllin as in previous step, and incubated for another 24 h. The cell culture supernatant was
harvested for HA tests. Values are mean ± SD from three replicates. Viral titers between each treated group and the untreated control group were compared by one-way
ANOVA followed by Dunnett’s multiple comparisons test. (ns: non-significant, ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, ⁄⁄⁄⁄p < 0.0001).
Table 1
Antiviral effect of different compounds on influenza viruses in MDCK cells.
Compound IC50 (nM)a
A/PR/8/34
(H1N1)
A/Aichi/2/68
(H3N2)
A/San Diego/1/2009 (H1N1
pdm09)
A/San Diego/21/2008
(H1N1)
A/San Diego/61/2008
(H1N1)
B/Taiwan/2/
62
Diphyllin 489.1 ± 14.32 38.32 ± 0.51 632.2 ± 3.67 372.8 ± 8.17 123.6 ± 2.98 139.8 ± 14.68
Amantadine >22,000 6.14 ± 0.45 NTb NTb NTb NTb
Oseltamivir NTb NTb NTb >40,000 NTb NTb
a IC50: the concentration of compound showed 50% inhibition of virus-induced cell cytopathic effect (mean ± SD).
b NT: not tested.
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vation supports that diphyllin could interfere with the low pH-
dependent membrane fusion between virus and intracellular
endosomes.
In the infection study with the GFP-expressing influenza virus,
the most significant inhibitory effect was obtained through the
pretreatment protocol, indicating that prior exposure to diphyllin
altered susceptibility of cells to influenza virus by regulating the
amount of acidified endosomes within the cells. Meanwhile, two
other tests of time-of-addition of diphyllin also exhibited inhibi-
tory effects against viruses comparing to the mock-treated group,
suggesting a concurrent treatment with diphyllin upon virus repli-
cation might be a worthwhile alternative when a prophylaxis is not
feasible.
Owing to the vast number of virus strains circulating world-
wide, we are seeking a drug that has a universal effect on influenzaviruses regardless of viral type/subtype. In this study, besides the
laboratory H1N1 strain A/PuertoRico/8/34 (PR8) which is resistant
to amantadine (Scholtissek and Faulkner, 1979) (had a IC50 of
amantadine higher than 22 lM), we tested avian influenza A
(H6N1) virus and five more types/subtypes of virus strains (Ta-
ble 1), including an H1N1 oseltamivir-resistant clinical isolate A/
San Diego/21/2008 (had a IC50 of oseltamivir higher than 40 lM).
The results clearly showed that diphyllin demonstrated CPE pro-
tection and inhibited influenza viral replication against multiple
types/subtypes, including the drug-resistant strains. To further
investigate the spectrum of antiviral activities of diphyllin, we
extended use of diphyllin to the context of dengue virus, another
emerging human pathogen that shares a similar pH-dependent
virus entry mechanism as influenza viruses (Pierson and Diamond,
2012). The results showed that diphyllin interfered with dengue
virus replication in cells, supporting the notion that diphyllin
(A)
(B)
Fig. 7. Combinations of diphyllin and oseltamivir showed enhanced antiviral effect and CPE protection. (A) Diphyllin (1000, 500 nM) and oseltamivir (1000, 500, 250 nM)
were used individually or in combination in NS1-GFP virus infected MDCK cells as described in Section 2.7. Cells were harvested for NP expression analysis using Western
blotting, and extracellular virus titers in supernatant were determined by an HA test. (B) Oseltamivir (25, 12.5, 6.25, 3.125 nM) was used in the absence or presence of
diphyllin (250, 125 nM) in NS1-GFP virus infected MDCK cells as described in Section 2.7. An MTT assay was performed and normalized cell viability was presented. Values
are mean ± SD from three replicates. Cell viability between each diphyllin cooperatively treated group and the amantadine alone treated group were compared by two-way
ANOVA followed by Dunnett’s multiple comparisons test. (ns: non-significant, ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, ⁄⁄⁄⁄p < 0.0001).
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bition. Also, multiple methods were used in this study to evaluate
diphyllin’s effect, including the assay of infectivity, investigation of
viral mRNA transcription by qRT-PCR and protein expression by
Western blot, examination of GFP expression as a surrogate read-
out for virus replication, CPE protection, and quantification of
extracellular virus particles using HA tests, all of which corrobo-
rated the antiviral effect of diphyllin.
The combinatorial effect of diphyllin was also studied by com-
bining a commercially available NA inhibitor (oseltamivir) or an
M2 ion channel blocker (amantadine) with diphyllin. The combina-
tion of diphyllin and amantadine showed an enhanced inhibitory
effect on both the virus expression and the CPE protection. Given
that amantadine functions by inhibiting a proton-pump on viral
antigens (Ciampor et al., 1992), thereby regulating vesicular pH in
an analogous fashion to diphyllin, the cooperativity between aman-
tadine and diphyllin is presumably due to a more complete inhibi-
tion of endosomal acidification that occurred when the two drugs
were combined. On the other hand, since diphyllin takes effect at
an early stage of the replication cycle (virus fusion/uncoating) while
oseltamivir takes effect at a later stage of the replication cycle (re-
lease of virons from infected cells), combining these two drugs was
hypothesized to result in a synergistic action. As expected, viral
protein expression and HA titer were significantly reduced when
combinations of these two drugs were given as compared to
single-drug treatments. Enhanced activity of oseltamivir on CPE
protection was also observed in combination with diphyllin. It
was reported that cell-based assays had less advantages than thedirect enzymatic measurement of NA for monitoring susceptibility
to the NA inhibitors (Tisdale, 2000). In our experimental setting,
however, we aimed to compare the combinatorial effect of diphyl-
lin with the NA inhibitor, rather than to measure the susceptibility
of viruses to certain NA inhibitors. Moreover, due to the different
sensitivity of assaymethods utilized in this study, the doses of com-
pound combinations were pre-optimized to reflect a dynamic range
that demonstrated appreciable interactions between the different
compounds. For instance, higher doses of compounds were used
in the Western blot and the HA test from Fig. 7A as compared to
those used in the CPE assay from Fig. 7B.
In contrast to the commonly used oseltamivir, it should be
noted that amantadine is not currently recommended for antiviral
treatment or chemoprophylaxis of human influenza A because of
extensive resistance observed among viral strains (Fiore et al.,
2011). The present study shows that diphyllin enhances amanta-
dine’s antiviral effect, which may aide the current effort in restor-
ing amantadine’s activity against amantadine-resistant influenza
virus strains using combination treatment (Nguyen et al., 2012).
In addition, antiviral effect of amantadine has been demonstrated
in equine influenza (Timoney, 1996; van Maanen and Cullinane,
2002), and it possesses therapeutic value in veterinary medicine.
As influenza viruses undergo rapid mutations and it is difficult to
predict the drug sensitivity of the new generation of viruses, drug
combinations with diphyllin or other v-ATPase inhibitors present a
valuable strategy to help combat antiviral resistance.
In summary, we herein demonstrate that diphyllin, a novel and
naturally potent v-ATPase inhibitor, alters cellular susceptibility to
(A)
(B)
Fig. 8. Combinations of diphyllin and amantadine showed enhanced antiviral effect and CPE protection. (A) Diphyllin (500, 250 nM) and amantadine (100, 50, 25 nM) were
used individually or in combination in A/Aichi/2/68(H3N2) virus infected MDCK cells as described in Section 2.7. Cells were harvested for NP expression analysis using
Western blotting, and extracellular virus titers in supernatant were determined by an HA test. (B) Amantadine (50, 25, 12.5, 6.25, 3.125 nM) was used in the absence or
presence of diphyllin (250, 125 nM) in A/Aichi/2/68(H3N2) virus infected MDCK cells as described in Section 2.7. An MTT assay was performed and normalized cell viability
was presented. Values are mean ± SD from three replicates. Cell viability between each diphyllin cooperatively treated group and the amantadine alone treated group were
compared by two-way ANOVA followed by Dunnett’s multiple comparisons test. (ns: non-significant, ⁄p < 0.05, ⁄⁄p < 0.01, ⁄⁄⁄p < 0.001, ⁄⁄⁄⁄p < 0.0001).
H.-W. Chen et al. / Antiviral Research 99 (2013) 371–382 381influenza viruses by inhibiting the endosomal acidification, which
leads to abrogation of virus replication in cells. Combinatorial
treatment of the host-targeting diphyllin with pathogen-targeting
therapeutics (oseltamivir and amantadine) demonstrates en-
hanced antiviral effect and cell protection in vitro. The in vivo use
of diphyllin awaits investigation using an animal model.
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